PRESS RELEASES

Date Title and Summary View
Toggle Summary Regulus Provides Update on Clinical Hold of RG-101
On Track to Deliver Follow-up Results from On-going RG-101 Studies
View HTML
Toggle Summary Regulus to Release Second Quarter Financial Results on August 2, 2016
Conference Call and Webcast to Follow
View HTML
Toggle Summary Regulus to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
LA JOLLA, Calif. , July 5, 2016 /PRNewswire/ --  Regulus Therapeutics Inc . (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Joseph "Jay" Hagan, Chief Operating Officer of Regulus, will present a
View HTML
Toggle Summary Regulus Reports Clinical Hold of RG-101
Timelines of On-going Studies are not Expected to be ImpactedConference Call Today at 5:00 p.m. ET
View HTML
Toggle Summary Regulus Secures $30 Million Growth Capital Credit Facility
LA JOLLA, Calif. , June 20, 2016 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it has entered into a $30 million loan and security agreement with Oxford
View HTML
Toggle Summary Regulus Reports Positive Top-line Data
- Results Demonstrate First Successful Shortened 4-week Treatment Regimen to Date -- Conference Call Today at 8:30 AM EST -
View HTML
Toggle Summary Regulus to Present at the Jefferies 2016 Healthcare Conference
LA JOLLA, Calif. , June 3, 2016 /PRNewswire/ -- Regulus Therapeutics Inc . (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Paul Grint , M.D., President and Chief Executive Officer of Regulus, will
View HTML
Toggle Summary Dr. Hugh Rosen Joins Regulus Board of Directors
LA JOLLA, Calif. , June 2, 2016 /PRNewswire/ --   Regulus Therapeutics Inc. ( NASDAQ : RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs (miR), today announced Hugh Rosen , M.D., Ph.D.
View HTML
Toggle Summary Regulus Expands Clinical Trial Collaboration with GSK
- Phase II Study Evaluating the Combination of RG-101 and GSK's Long-Acting Parenteral (LAP) Formulation of GSK2878175 as a potential single-visit cure to begin Q4 2016- Ongoing Phase II RG-101 and oral GSK2878175 Combination Study on Track to Report Interim Results by Year-end -
View HTML
Toggle Summary Regulus Appoints Allison Wey as Vice President, Investor Relations & Corporate Communications
LA JOLLA, Calif. , May 23, 2016 /PRNewswire/ --  Regulus Therapeutics Inc . ( NASDAQ : RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that Allison Wey has been appointed Vice President, Investor Relations and
View HTML